Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 2/20 | 0.79 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.61 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.61 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.61 |
| ▸ | LDHA | P00338 | 1/20 | 0.61 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.61 |
| ▸ | FBP1 | P09467 | 1/20 | 0.61 |
| ▸ | SRC | P12931 | 1/20 | 0.61 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.61 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.61 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.61 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.61 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.61 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.61 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2217172 | 1.00 | ADORA1 (0.79) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL29384615 | 1.00 | ADORA1 (0.79) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL17438017 | 0.96 | ADORA1 (0.79) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL8325770 | 0.94 | ADORA1 (0.85) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL30670292 | 0.92 | ADORA1 (0.76) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL4296364 | 0.92 | ADORA1 (0.69) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL15329077 | 0.92 | ADORA1 (0.75) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL30582997 | 0.92 | ADORA1 (0.75) | ADORA1DNPH1PRKAB2TRPM2LDHA | |
| SCHEMBL21314872 | 0.90 | ADORA1 (0.64) | ADORA1SMN1; SMN2 | |
| SCHEMBL29384896 | 0.90 | ADORA1 (0.64) | ADORA1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 955 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026107341-A1 | COMBINATION THERAPY FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION | Vir Biotechnology, Inc. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4745239-A1 | CFB INHIBITOR COMPOSITION AND USE THEREOF | Rigerna Therapeutics Co., Ltd. (CN) | 2026-05-20 | — | — | EP | claimed |
| EP-4714500-A2 | HEPATITIS B VIRUS (HBV) DSRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| EP-3837366-B1 | HEPATITIS B VIRUS (HBV) DSRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS INC (US) | 2026-02-18 | — | — | EP | claimed |
| US-20260022161-A1 | COMBINATION HBV THERAPY | VIR BIOTECHNOLOGY INC (US) | 2026-01-22 | — | — | US | claimed |
| EP-4656656-A2 | COMBINATION HBV THERAPY | Humabs BioMed SA (CH) | 2025-12-03 | — | — | EP | claimed |
| US-20250320497-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION AND HBV-ASSOCIATED DISEASES | VIR BIOTECHNOLOGY INC (US) | 2025-10-16 | — | — | US | claimed |
| EP-4285929-B1 | COMBINATION HBV THERAPY | HUMABS BIOMED SA (CH) | 2025-10-08 | — | — | EP | claimed |
| US-20250302951-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS D VIRUS (HDV) INFECTION AND ASSOCIATED DISEASES | Vir Biotechnology, Inc. | 2025-10-02 | — | — | US | claimed |
| US-20250304967-A1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2025-10-02 | — | — | US | claimed |
| WO-2021096763-A1 | METHODS AND COMPOSITIONS FOR TREATING AN ANGIOTENSINOGEN- (AGT-) ASSOCIATED DISORDER | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-05-20 | — | — | WO | claimed |
| WO-2020036862-A9 | HEPATITIS B VIRUS (HBV) dsRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-03-11 | — | — | WO | claimed |
| US-10933081-B2 | Myostatin iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-03-02 | — | — | US | claimed |
| US-10934544-B2 | Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof | Alny lam Pharmaceuticals, Inc. (US) | 2021-03-02 | — | — | US | claimed |
| EP-3728593-A1 | HIGH MOBILITY GROUP BOX-1 (HMGB1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | Alnylam Pharmaceuticals, Inc. (US) | 2020-10-28 | — | — | EP | claimed |
| US-20200308588-A1 | HIGH MOBILITY GROUP BOX-1 (HMGB1) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-10-01 | — | — | US | claimed |
| US-20200138847-A1 | MYOSTATIN IRNA COMPOSITIONS AND METHODS OF USE THEREOF | BANK OF AMERICA, N.A. | 2020-05-07 | — | — | US | claimed |
| US-10640770-B2 | Hepatitis D virus (HDV) iRNA compositions and methods of use thereof | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-05-05 | — | — | US | claimed |
| EP-3146049-B1 | ANGIOTENSINOGEN (AGT) IRNA COMPOSITIONS AND METHODS OF USE THEREOF | ALNYLAM PHARMACEUTICALS INC (US) | 2020-02-26 | — | — | EP | claimed |
| US-10478500-B2 | Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-11-19 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260022161-A1 | COMBINATION HBV THERAPY | NSUN2, RNMT, RNGTT | ADORA1 154/4885DNPH1 1382/4885PRKAB2 1112/4885 |
| US-20250304967-A1 | 17BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | HSD17B13, HSD17B3, HSD17B1 | ADORA1 3179/4885DNPH1 2075/4885PRKAB2 956/4885 |
| US-10934544-B2 | Factor XII (hageman factor) (F12), kallikrein B, plasma (fletcher factor) 1 (KLKB1), and kininogen 1 (KNG1) iRNA compositions and methods of use thereof | KLKB1, F12, F13A1 | ADORA1 1831/4885DNPH1 4751/4885PRKAB2 1671/4885 |
| US-20250302951-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS D VIRUS (HDV) INFECTION AND ASSOCIATED DISEASES | DNTT, HAVCR2, POLRMT | ADORA1 1022/4885DNPH1 1647/4885PRKAB2 2459/4885 |
| US-10478500-B2 | Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression | HAO1, HAO2, ACOX1 | ADORA1 1080/4885DNPH1 1413/4885PRKAB2 3932/4885 |
| US-10640770-B2 | Hepatitis D virus (HDV) iRNA compositions and methods of use thereof | HAVCR2, EIF2AK2, CDV3 | ADORA1 2447/4885DNPH1 3766/4885PRKAB2 3890/4885 |
| US-20250320497-A1 | COMPOSITIONS AND METHODS FOR TREATING HEPATITIS B VIRUS (HBV) INFECTION AND HBV-ASSOCIATED DISEASES | IFNAR1, IFNG, HAVCR2 | ADORA1 1635/4885DNPH1 3792/4885PRKAB2 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.